The company's first commercial application will be for dialysis patients, addressing the severe unmet clinical need for safe, long-term dialysis access, while reducing costs and improving patient outcomes. Healionics has additional products in development, including an implantable port for needle-free dialysis and a platform biomaterial that can improve the performance of a wide range of implantable devices. The company is currently conducting human studies of STARgraft and has a large patent portfolio.